The honest bottom line belongs at the top: the clinical record for vasoactive intestinal peptide and its synthetic form aviptadil is real, but no trial has yet converted that biology into a confirmed benefit on a hard clinical endpoint. The strongest human data sit in small mechanistic and early-phase respiratory work, the largest randomized trials ran mixed to negative, and the wellness and chronic-illness uses the molecule is best known for rest on the thinnest evidence of all. Understanding which tier a given claim comes from is the difference between reading a proof of mechanism and reading a proven treatment.
Aviptadil has never been approved by the FDA for any respiratory indication, and neither of the two controlled programs in COVID-19 respiratory failure met its primary endpoint.
Two controlled programs dominate the intravenous record, and they were built so differently that the design gap explains most of the disagreement between them. One was sponsor-run with a wide severity range and a composite endpoint; the other was a National Institutes of Health platform trial with uniform criteria, independent randomization, and an ordinal outcome. For anyone weighing what the drug has actually been shown to do, the architecture of the study matters as much as the result it reported.
| Design element | Sponsor-run phase 2b/3 | ACTIV-3b / TESICO |
|---|---|---|
| Population | Roughly 196 hospitalized adults with COVID-19 respiratory failure | Critically ill adults with COVID-19 respiratory failure, multi-site |
| Severity range | High-flow nasal cannula through mechanical ventilation and extracorporeal support | Uniform enrollment criteria across academic sites |
| Regimen | Continuous intravenous infusion, three ascending doses over twelve hours on three consecutive days | Factorial design testing aviptadil and remdesivir under a master protocol |
| Primary endpoint | Alive and free of respiratory failure at day 60 | Ordinal clinical status at day 90 |
| Conduct | Sponsor held the analysis chain | Blinded placebo control, prespecified interim monitoring, stopped early for futility |
The two controlled intravenous programs judged aviptadil against different primary endpoints, a day 60 alive-and-free composite versus a day 90 ordinal outcome, and no adequately powered randomized trial has tested the drug in non-COVID acute respiratory distress syndrome.
Neither program produced a confirmed clinical win, and the distance between what was emphasized and what was demonstrated is the whole story here. The sponsor-run trial missed its primary endpoint across the randomized population and reported significance inside a prespecified severity stratum, a hypothesis-generating result in a trial small enough for chance imbalance to move the numbers. The independently monitored platform arm, enrolling a sicker and more uniform population, reached a cleaner and less encouraging verdict.
Cumulative mortality through day 90 in the independently run platform trial was 38 percent on aviptadil against 36 percent on placebo, and that comparison was closed early for futility.
Pulmonary arterial hypertension was one of the most biologically defensible targets ever proposed for this peptide, which is exactly why its collapse under proper controls is instructive. The evidence arrived in a familiar sequence: a deficiency rationale, a small open-label study with striking numbers that circulated widely, then a placebo-controlled trial in which the effect vanished. The endpoint distinction is worth holding onto, since pulmonary vascular resistance is a direct catheter measurement while six-minute walk distance is a functional composite, and a drug can move one without touching the other.
The favorable acute hemodynamics reported in an eight-patient open-label inhalation study did not survive a larger placebo-controlled phase 2 trial, which found no significant effect on exercise capacity or pulmonary hemodynamics and was never fully published.
Sarcoidosis produced the cleanest demonstration that this peptide does something measurable inside human lungs, and also the clearest example of biomarker movement without a matching clinical endpoint. Roughly twenty patients nebulized the peptide daily for about four weeks, with bronchoalveolar lavage before and after sampling the airway compartment directly instead of relying on blood. The immunologic result was coherent and the functional result was absent, and both halves matter to anyone reading a headline about this study.
| Endpoint domain | Airway immune markers | Lung function |
|---|---|---|
| How measured | Bronchoalveolar lavage before and after treatment | Standard functional testing |
| Result | Alveolar macrophage tumor necrosis factor alpha fell; regulatory T cell proportion and suppressive activity rose | No matching gain reported |
| Exposure window | Daily nebulization for about four weeks | The same four weeks |
| Randomized confirmation | None to date | None to date |
The phase 2 inhalation study in roughly twenty patients with pulmonary sarcoidosis reported lower alveolar macrophage tumor necrosis factor alpha and higher regulatory T cell numbers in lavage fluid with no accompanying improvement in lung function.
This is the weakest link in the whole evidence chain, and it deserves plain description rather than hedging. A fluctuating, symptom-defined condition treated with a nasal spray in unblinded studies is close to the ideal circumstance for regression to the mean and expectancy effects to produce apparent improvement. Chronic inflammatory response syndrome as a biotoxin-driven entity is itself not widely accepted as an established diagnosis, so the population under study is not consistently defined between clinicians.
The published intranasal evidence in chronic inflammatory response syndrome contains no randomized, placebo-controlled trial and no independent replication outside the originating research group.
The move into human respiratory trials was not opportunistic; it rested on an unusually specific piece of anatomy that made the lung look like the right organ for this molecule. That rationale is genuine science, and it is also a textbook illustration of why preclinical strength predicts human success so poorly in critical care. Animal models deliver one defined insult to a healthy young organism and dose at or before injury, while a critically ill patient arrives days into a multi-organ process in which the cell population the drug protects has already been lost.
Roughly seventy percent of the peptide's binding in the lung occurs on alveolar type II cells through the VPAC1 receptor, the surfactant-producing cells that SARS-CoV-2 enters via angiotensin-converting enzyme 2.
Tolerability is the strongest part of this drug's clinical record, which is a slightly awkward compliment for a molecule that has not yet proven benefit. The treatment-emergent events attributed to it across the respiratory trials were largely predictable extensions of its normal physiology rather than unexpected toxicities, and no safety monitoring board stopped an arm for toxicity. The exposure pattern used outside of trials, repeated over months, is the pattern the safety data does not cover.
Essentially all controlled exposure to aviptadil has lasted only days, so nothing meaningful is known about repeated courses, chronic dosing, immunogenicity, or long-term effects.
Pharmacokinetics is the quiet reason so much of this literature is hard to interpret. A molecule cleared from plasma in a couple of minutes has no dose in the sense an orally bioavailable drug does, so every systemic study is really a study of an infusion rate, and cross-study comparison means comparing exposure profiles rather than milligram amounts. That constraint reaches straight into endpoint design, since a drug present only while it is infusing cannot plausibly be credited with an effect at day 60 unless the mechanism is a durable structural rescue.
Native vasoactive intestinal peptide is cleared from plasma in roughly one to two minutes, so every systemic study measures an infusion rate rather than a discrete dose.
Regulatory status is where the gap between this molecule's reputation and its paperwork is widest. Designations are routinely quoted as if they were endorsements, and access mechanisms used during the pandemic are routinely read as agency agreement, when neither involves any finding that the drug works. Sorted by actual regulatory weight, the picture is short at the top and crowded at the bottom.
The FDA has never approved aviptadil for respiratory failure, acute respiratory distress syndrome, sarcoidosis, or any systemic indication, and declined an emergency use authorization for critical COVID-19 citing insufficient evidence of benefit.
The list of entirely unsupported uses is longer than the supported one, and it includes most of what the peptide is popularly credited with. Inside the respiratory space the most conspicuous hole is that the mechanism motivating the whole program, protection of alveolar type II cells and surfactant, has never been tested against the general form of the injury it targets. The obstacle is economic as much as scientific: the native peptide is old and off-patent with limited commercial upside, so confirmatory work realistically depends on public funding, academic consortia, or a proprietary long-acting analogue.
No controlled human evidence supports this peptide in cognitive decline, chronic fatigue, mold-related illness, long COVID, autoimmune disease generally, or as a broad anti-inflammatory or longevity intervention.
Educational use only. This article describes what the published scientific and clinical literature reports about Vasoactive Intestinal Peptide (VIP). It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
